Morgan Stanley analyst Sarita Kapila upgraded Grifols to Overweight from Equal Weight with a price target of EUR 14, up from EUR 13. The analyst expects 2023 will be a “strong growth year” for the company, supported by accelerating plasma collections and early signs of declining donor fees. Grifols is at an inflection point, with potential for faster de-leveraging and competitive headwinds subsiding next year, Kapila tells investors in a research note. The company “now offers the strongest earnings growth outlook in 2023 amongst mid-cap pharma peers,” contends the analyst.
previous post